Die systemische Therapie beim kurablen Mammakarzinom wird zunehmend der Operation im Sinne einer «neo-adjuvanten» Behandlung -oder besser primär systemischen Therapie (PST) -vorangestellt. Sowohl aus klinischen als auch aus wissenschaftlichen Gründen bietet dieses Behandlungskonzept viele Vorteile. Für die Betroffenen steht die Möglichkeit im Vordergrund, die Rate der brusterhaltenden Operationen erhöhen zu können. Nicht zu vernachlässigen ist auch der positive psychologische Effekt, der durch das Schrumpfen, und somit Ansprechen des Tumors auf die Therapie, erreicht wird. Nichtsdestotrotz stellt aber die PST eine große Herausforderung für die Kliniker dar, sowohl im Therapieverlauf als auch während und nach der Operation mit den erzielten Veränderungen am Gewebe umzugehen.
Introduction
From time to time, primary systemic therapy (PST) is more commonly used as the primary therapeutic option in patients with non-metastatic breast cancer. PST was first applied to patients with locally advanced, inoperable cancers. During the last 15 years, many studies have shown sufficient results which demonstrate the safety and efficiency of PST. Subsequently, this kind of therapy could also be applied to patients with smaller tumors.
Current recommendations for PST are periodically reviewed [1] . However, new questions concerning the PST practice do occur: Which are the advantages / disadvantages of PST compared to adjuvant treatment? Can the choice of treatment be optimized or adapted to a special type of tumor? Are there tumors that are stimulated rather than eliminated by PST, and does clinical examination provide sufficient safety for patients? Which challenges appear concerning surgery after PST, and can the established guidelines be used or do they have to be replaced by new rules? Is patient monitoring including pal-pation, mammography and ultrasound sufficient during therapy? Or do other imaging diagnostics, such as positron emission tomography (PET) or magnetic resonance imaging (MRI), have to be employed for an early evaluation of a successful therapy? Which information can provide an in vivo test from the tumor during PST, and how can these results be utilized for further treatment? And last but not least, what about patients who do not show any therapy response and are, in a way, therapy-resistant or show signs of progression? At the moment, many of these questions cannot be answered. This overview discusses current data regarding surgical procedure after PST.
Does PST Contribute to an Increased Rate of Breast Conserving Therapy?
Long-term scientific observations of randomized multicenter studies comparing adjuvant chemotherapy with PST have shown no difference in disease free survival (DFS) and overall survival (OS) [2] [3] [4] [5] [6] . Subsequently, PST is considered to be a safe alternative to adjuvant chemotherapy. However, PST provides the positive effect of significantly increasing the rate of breast conserving therapies (table 1). The difficulty for the surgeon consists in deciding whether tumor-free excision margins can be gained. For this purpose, precise diagnostic checkup examinations during therapy (e.g. ultrasound, mammography, palpation, metric photo documentation) are necessary. In the case of a clinical complete remission (cCR), the tumor bed has to be tagged and excised based on the checkup data. Additionally, the tumor response rate can vary considerably (table 1) . This explains why the re-operation rate is comparatively higher (up to 20%). Views differ on whether the excision should take place within the 'old' or 'new' tumor margins. An excision within the old tumor margins ensures that even scattered tumor islands are captured. On the other hand, in these cases, a breast conserving therapy is not possible or cosmetically not sustainable. As explained in the following text, the local recurrence rate after PST in comparison to adjuvant systemic therapy is not significantly increased. This justifies operating primarily within the new tumor borders, and, as far as histologically verified, to make no further advances. By use of a preoperative hormonal therapy, the rate of breast conserving therapy can also be increased (table 2) . However, currently, this kind of therapy is an alternative to neoadjuvant chemotherapy only for elder patients who have hormone receptor-positive tumors, a bad performance status and suffer from internal diseases. An important parameter to evaluate the result of PST is the rate of pathological complete remissions (pCR) which represents a significant predictor for DFS [7] . Patients with tumors that could be eliminated completely (pCR) by PST had by comparison a significantly better disease-related survival rate (DFS, OS) [2, 4] . It is not clear whether the elimination of invasive tumor parts can be seen as a pCR, or whether any invasive and pre-invasive tumor cells have to be absent in both the breast and lymph tissue. [3] 893 34 71 EORTC [4] 698 21 37 Scholl [5] 390 77 82 NSABP B-27 [11] 2,189 61 63 Gepar-duo [12] 913 66 75 AGO [13] 678 50 61 Gepartrio-Pilot [14] 286 72 ACTH = Adjuvant chemotherapy; PST-1/2 = primary systemic chemotherapy regimen 1/2; BCT = breast conserving therapy. 
Is the Local Recurrence Rate Different after PST and Surgery?
A metaanalysis consisting of 9 studies (approximately 4,000 patients) gives evidence of a significant increase in the local recurrence rate (RR = 1.22, 95% confidence interval (CI) 1.04-1.43; p = 0.015) [8] . When scrutinizing, it emerges that the authors describe a very high local recurrence rate in 3 studies. In these studies, considerably more patients received radiation therapy directly after PST without surgery (as compared to adjuvant therapy patients). It is more a problem of deviating from standard procedure than a significant increase in local recurrence after PST. Nowadays, according to standard procedure with surgery and postoperative radiotherapy, there is no significant increase in local recurrence although there is a tendency for increased recurrence in the PST group (table 3) . Chen et al. [8] were able to prove that with the following parameters the risk of local and locoregional recurrence is significantly higher: clinical N2/3 tumors, rest tumor after PST > 2 cm, multifocal tumor, and lymphovascular invasion. Presently, there is a common consensus that after breast conserving therapy beyond PST external beam radiation therapy should be done. A future option may be to combine simultaneous intraoperative radiotherapy with external beam radiotherapy to achieve a decreased local recurrence rate. Intraoperative radiotherapy has the advantage of detecting the primary tumor location and hence to protect neighboring tissue.
What is the Ranking of Sentinel Node Biopsy after PST?
With sentinel node biopsy, a decrease in morbidity can be achieved. Now, the question arises whether sentinel node biopsy after PST is safe enough. Various questions arise: Is there any change after PST in the lymphatic pattern of the breast? Is the effect of the therapy in the sentinel node the same as in the nonsentinel node? Is the sentinel node biopsy after downstaging in the axilla (before PST N+, after PST N-) reliable? Most of these questions have not yet been completely answered. Randomized studies have to be carried out to find satisfactory answers. In a metaanalysis Xing et al. [19] collected the data of 21 studies with 1,273 patients (table 4) . The median detection rate was 90% (72-100%, 95% CI 85-90%), sensitivity 88% (67-100%, 95% CI 84-91%). The authors concluded that the sentinel node biopsy was a reliable procedure after PST. The most important study out of this metaanalysis with 428 patients did not find any significant differences in the detection rate of the sentinel node in relation to age, tumor size, nodal status, and location of the tumor [10] . However, a non significant increase in the false-negative rate was detected with increasing tumor size (≤ 2cm: 5%; 2.1-4 cm: 9.7%; > 4 cm: 13.8%; p = 0.33). Overall, the safety of sentinel node biopsy is high enough taking into consideration all criteria (before PST: tumor size < 3 cm, N0, sufficient clinical experience). But sentinel node biopsy should not be performed outside of randomized studies. One innovative approach is to carry out sentinel node biopsy before PST. The information gained could additionally support the indication for PST in cases of positive lymph nodes. 
